C-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer

Oncogene

Volumn 31, Issue 7, 2012, Pages 869-883

  Regan, J L ^a   Kendrick, H ^a   Magnay, F A ^a   Vafaizadeh, V ^b   Groner, B ^b   Smalley, M J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Brca1; c Kit; mammary; progenitor

Indexed keywords

BRCA1 PROTEIN; ESTROGEN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOGENE C KIT; PRIORITY JOURNAL; STEM CELL;

ANIMALS; APOPTOSIS; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; EPITHELIAL CELLS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MUTATION; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS C-KIT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84857115071     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.289     Document Type: Article

References (56)

1. Altiok S, Batt D, Altiok N, Papautsky A, Downward J, Roberts TM et al. (1999). Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells. J Biol Chem 274: 32274-32278.
2. Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA. (2011). Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res 13: R11.
3. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC et al. (2007). Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9: 201-209. (Pubitemid 46420863)
4. Barton J, Liggett W, Mainwaring M, Hainsworth JD, Simons L, Spigel DR et al. (2006). Phase II pilot trial of imatinib mesylate with weekly docetaxel in metastatic breast cancer. J Clin Oncol 24: 10716.
5. Baxter LL, Hou L, Loftus SK, Pavan WJ. (2004). Spotlight on spotted mice: a review of white spotting mouse mutants and associated human pigmentation disorders. Pigment Cell Res 17: 215-224. (Pubitemid 38724551)
6. Brannan CI, Lyman SD, Williams DE, Eisenman J, Anderson DM, Cosman D et al. (1991). Steel-Dickie mutation encodes a c-kit ligand lacking transmembrane and cytoplasmic domains. Proc Natl Acad Sci USA 88: 4671-4674. (Pubitemid 21914603)
7. Britt KL, Kendrick H, Regan JL, Molyneux G, Magnay FA, Ashworth A et al. (2009). Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells. Breast Cancer Res 11: R20.
8. Brizzi MF, Dentelli P, Rosso A, Yarden Y, Pegoraro L. (1999). STAT protein recruitment and activation in c-Kit deletion mutants. J Biol Chem 274: 16965-16972.
9. Caruana G, Cambareri AC, Ashman LK. (1999). Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene 18: 5573-5581. (Pubitemid 29481504)
10. Chew HK, Barlow W, Albain K, Lew D, Budd T, Allen G et al. (2006). SWOG 0338: A phase II trial of imatinib mesylate in combination with capecitabine in metastatic breast cancer. J Clin Oncol 24: 10529.
11. Chin H, Arai A, Wakao H, Kamiyama R, Miyasaka N, Miura O. (1998). Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood 91: 3734-3745. (Pubitemid 28225741)
12. Clarke RB, Howell A, Potten CS, Anderson E. (1997). Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57: 4987-4991. (Pubitemid 27498105)
13. Deberry C, Mou S, Linnekin D. (1997). Stat1 associates with c-kit and is activated in response to stem cell factor. Biochem J 327(Part 1): 73-80. (Pubitemid 27455463)
14. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. (2003). Stem cells in normal breast development and breast cancer. Cell Prolif 36(Suppl 1): 59-72. (Pubitemid 37521844)
15. Driessen RL, Johnston HM, Nilsson SK. (2003). Membrane-bound stem cell factor is a key regulator in the initial lodgment of stem cells within the endosteal marrow region. Exp Hematol 31: 1284-1291. (Pubitemid 37510034)
16. Fernandez-Gonzalez R, Illa-Bochaca I, Welm B, Fleish MC, Werb Z, Ortiz-deSolorzano C et al. (2009). Mapping mammary gland architecture using multi-scale in situ analysis. Integr Biol 1: 80-89.
17. Gao B, Shen X, Kunos G, Meng Q, Goldberg ID, Rosen EM et al. (2001). Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 488: 179-184. (Pubitemid 32103593)
18. Gommerman JL, Rottapel R, Berger SA. (1997). Phosphatidylinositol 3-kinase and Ca2+ influx dependence for ligand-stimulated internalization of the c-Kit receptor. J Biol Chem 272: 30519-30525. (Pubitemid 27512265)
19. Gommerman JL, Sittaro D, Klebasz NZ, Williams DA, Berger SA. (2000). Differential stimulation of c-Kit mutants by membranebound and soluble Steel Factor correlates with leukemic potential. Blood 96: 3734-3742.
20. Gusterson BA, Ross DT, Heath VJ, Stein T. (2005). Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7: 143-148. (Pubitemid 40872776)
21. Haley BB, Ashfaq R, DeHaas M, Ramaswami A, Sikder K, Tripathy D. (2007). A phase I/II study of imatinib and docetaxel as neoadjuvant therapy in locally advanced breast cancer. J Clin Oncol 25: 11039.
22. Hayashi S, Kunisada T, Ogawa M, Yamaguchi K, Nishikawa S. (1991). Exon skipping by mutation of an authentic splice site of c-kit gene in W/W mouse. Nucleic Acids Res 19: 1267-1271. (Pubitemid 21913213)
23. Huang S, Guo YP, May G, Enver T. (2007). Bifurcation dynamics in lineage-commitment in bipotent progenitor cells. Dev Biol 305: 695-713. (Pubitemid 46705410)
24. Kendrick H, Regan JL, Magnay FA, Grigoriadis A, Mitsopoulos C, Zvelebil M et al. (2008). Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 9: 591.
25. Kent D, Copley M, Benz C, Dykstra B, Bowie M, Eaves C. (2008). Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clin Cancer Res 14: 1926-1930. (Pubitemid 351551100)
26. Kordon EC, Smith GH. (1998). An entire functional mammary gland may comprise the progeny from a single cell. Development 125: 1921-1930. (Pubitemid 28274378)
27. Lilla JN, Werb Z. (2010). Mast cells contribute to the stromal microenvironment in mammary gland branching morphogenesis. Dev Biol 337: 124-133.
28. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15: 907-913.
29. Linnekin D, DeBerry CS, Mou S. (1997). Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J Biol Chem 272: 27450-27455. (Pubitemid 27452714)
30. Mallepell S, Krust A, Chambon P, Brisken C. (2006). Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci USA 103: 2196-2201. (Pubitemid 43271646)
31. Mansson R, Hultquist A, Luc S, Yang L, Anderson K, Kharazi S et al. (2007). Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. Immunity 26: 407-419. (Pubitemid 46603001)
32. Miyazawa K, Williams DA, Gotoh A, Nishimaki J, Broxmeyer HE, Toyama K. (1995). Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 85: 641-649.
33. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R et al. (2010). BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells. Cell Stem Cell 7: 403-417.
34. Molyneux G, Regan J, Smalley MJ. (2007). Mammary stem cells and breast cancer. Cell Mol Life Sci 64: 3248-3260.
35. Ouchi T, Lee SW, Ouchi M, Aaronson SA, Horvath CM. (2000). Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. Proc Natl Acad Sci USA 97: 5208-5213. (Pubitemid 30313697)
36. Pathan NI, Geahlen RL, Harrison ML. (1996). The protein-tyrosine kinase Lck associates with and is phosphorylated by Cdc2. J Biol Chem 271: 27517-27523. (Pubitemid 26367314)
37. Reith AD, Ellis C, Lyman SD, Anderson DM, Williams DE, Bernstein A et al. (1991). Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J 10: 2451-2459. (Pubitemid 21905718)
38. Roskoski Jr R. (2005a). Structure and regulation of Kit proteintyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 338: 1307-1315. (Pubitemid 41608395)
39. Roskoski Jr R. (2005b). Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 337: 1-13. (Pubitemid 41393751)
40. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML et al. (2006). Generation of a functional mammary gland from a single stem cell. Nature 439: 84-88. (Pubitemid 43053633)
41. Shivakrupa R, Linnekin D. (2005). Lyn contributes to regulation of multiple Kit-dependent signaling pathways in murine bone marrow mast cells. Cell Signal 17: 103-109. (Pubitemid 39286785)
42. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. (2007). Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 176: 19-26. (Pubitemid 46041676)
43. Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ. (2006). CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res 8: R7.
44. Smalley MJ. (2010). Isolation, culture and analysis of mouse mammary epithelial cells. In: Ward A, Tosh D (eds). Methods in Molecular Biology. Springer: Berlin, pp 139-170.
45. Smart CE, Wronski A, French JD, Edwards SL, Asselin-Labat ML, Waddell N et al. (2011). Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit. Oncogene 30: 1597-1607.
46. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D et al. (2006). Purification and unique properties of mammary epithelial stem cells. Nature 439: 993-997. (Pubitemid 43292419)
47. Sun J, Pedersen M, Ronnstrand L. (2008). Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit. J Biol Chem 283: 27444-27451.
48. Taddei I, Deugnier MA, Faraldo MM, Petit V, Bouvard D, Medina D et al. (2008). Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol 10: 716-722. (Pubitemid 351772937)
49. Vafaizadeh V, Klemmt P, Brendel C, Weber K, Doebele C, Britt K et al. (2010). Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells 28: 928-938.
50. Vidarsson H, Mikaelsdottir EK, Rafnar T, Bertwistle D, Ashworth A, Eyfjord JE et al. (2002). BRCA1 and BRCA2 bind Stat5a and suppress its transcriptional activity. FEBS Lett 532: 247-252. (Pubitemid 35375898)
51. Voytyuk O, Lennartsson J, Mogi A, Caruana G, Courtneidge S, Ashman LK et al. (2003). Src family kinases are involved in the differential signaling from two splice forms of c-Kit. J Biol Chem 278: 9159-9166. (Pubitemid 36800397)
52. Wang H, Shao N, Ding QM, Cui J, Reddy ES, Rao VN. (1997). BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. Oncogene 15: 143-157. (Pubitemid 27344554)
53. Waterhouse DM, Mainwaring M, Barton J, Webb C, Markus TM, Spigel DR et al. (2008). Phase II pilot results of imatinib mesylate with weekly docetaxel in metastatic breast cancer. J Clin Oncol 26: May 20 Suppl; abstr 1090.
54. Westbury CB, Reis-Filho JS, Dexter T, Mahler-Araujo B, Fenwick K, Iravani M et al. (2009). Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ERalpha) in response to therapeutic radiation. J Pathol 219: 131-140.
55. Young SM, Cambareri AC, Odell A, Geary SM, Ashman LK. (2007). Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor. Cell Signal 19: 2572-2581. (Pubitemid 47542299)
56. Yu M, Luo J, Yang W, Wang Y, Mizuki M, Kanakura Y et al. (2006). The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J Biol Chem 281: 28615-28626. (Pubitemid 44507004)